TempraMed Technologies has signed a definitive exclusive commercial distribution agreement with Guri AAO (Guri) to market and sell TempraMed's full product line across the retail market in Israel.

This agreement marks a milestone in TempraMed's worldwide commercialisation strategy as the company accelerates its pivot from a direct-to-consumer online model toward large-scale retail pharmacy networks and B2B medical payers. This transition aligns with the company's long-term strategy to improve global access, reduce patient acquisition costs, and integrate its temperature-control solutions directly into the standard-of-care for millions of patients requiring temperature-sensitive medications.

By securing exclusive rights to TempraMed's VIVI line and upcoming temperature-sensitive medical storage products, Guri will play a central role in bringing TempraMed's solutions to a market known for early adoption of advanced medical technologies and strong consumer engagement in diabetes management and chronic care.

"TempraMed is an innovative, cutting-edge and revolutionary company that is transforming how temperature-sensitive medication is stored. TempraMed has created a category of its own, with literally no competition in market. We know the demand for its product line is high, as we conducted comprehensive checks and consultations with professional opinion leaders, retailers, and pharmacists, all of whom were amazed and impressed by TempraMed's product portfolio. Retail executives have already expressed a strong willingness to start selling the products. I'm proud to be among the first distributors of TempraMed products in the global market and am fully confident that this partnership will contribute to Guri's business growth and reputation, enriching our product portfolio and expanding into new categories," said Oded Guri, owner and CEO, Guri AAO.

The agreement with Guri represents the first of several new regional partnerships as TempraMed executes a global expansion programme covering Europe, the Middle East, North America, and Asia. With eight patents and regulatory approvals across major jurisdictions, TempraMed's products are positioned to meet growing demand from health systems and payors requiring regulated, compliant cold-chain solutions for injectables, biologics, fertility medications, GLP-1 therapies, and insulin.

"As we expand globally, our focus is on embedding TempraMed's technology within the retail and clinical ecosystems where patients already receive care. Partnering with a top-tier distributor like Guri aligns perfectly with our pivot from a digital B2C model to pharmacy-led distribution and B2B payor channels. This is a major step in making temperature-safe medication storage the global standard, improving outcomes, reducing wastage, and enhancing safety for patients who rely on temperature-sensitive therapies every single day," said Ron Nagar, CEO, TempraMed.